Late-onset of pulmonary embolism following hospitalization for COVID-19 despite thromboprophylaxis: a report of two cases

The global pandemic caused by the SARS-CoV-2 has resulted in an increased incidence of venous thromboembolism among hospitalized COVID-19-patients, especially those who required intensive care, despite thromboprophylaxis. This has resulted in the use of higher doses of thromboprophylaxis or therapeu...

Full description

Saved in:
Bibliographic Details
Published in:The Pan African medical journal 2021-03, Vol.38 (226)
Main Authors: Brem, Falmata Laouan, Missaoui, Zakariae, Arghal, Mohammed, Rasras, Hammam, Aichouni, Narjisse, Skiker, Imane, El Ouafi, Noha, Zakaria, Bazid
Format: Article
Language:English
Subjects:
Anticoagulants
Cardiology
Case Report
Case reports
coagulopathy
Coronaviruses
COVID-19
Dyspnea
Fever
Hospitalization
Laboratories
Medical imaging
Molecular weight
Oxygen saturation
Patients
Pneumonia
Polymerase chain reaction
post-discharge
Pulmonary arteries
pulmonary embolism
Pulmonary embolisms
Severe acute respiratory syndrome coronavirus 2
Thromboembolism
Veins & arteries
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The global pandemic caused by the SARS-CoV-2 has resulted in an increased incidence of venous thromboembolism among hospitalized COVID-19-patients, especially those who required intensive care, despite thromboprophylaxis. This has resulted in the use of higher doses of thromboprophylaxis or therapeutic anticoagulation therapy even in the absence of thrombotic events. However, after their hospital discharge, authors and current guidelines are not unanimous about extended anticoagulant therapy in patients with COVID-19. Here, we report two pulmonary embolism cases following hospitalization for COVID-19, despite intermediate doses of thromboprophylaxis. These rare cases suggest that there may be a residual thrombotic risk following hospitalization for COVID-19 and highlight questions about extended prophylactic-anticoagulation therapy after hospital discharge of patients with COVID-19.
ISSN:1937-8688
1937-8688
DOI:10.11604/pamj.2021.38.226.28503